Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9550830B2 · kind B2 · utility
10Cited by
62References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2013 |
| Grant date | Jan 24, 2017 |
| Priority date | — |
| Expiry date | Apr 4, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.